Title:
CCR4 ANTAGONISTS
Document Type and Number:
WIPO Patent Application WO/2023/205618
Kind Code:
A9
Abstract:
Compounds are provided having formula (I) wherein the groups/letters R1a, R1b, m, R2, R3, R4, X, Y, A, B, n, q, L and Q, have the meanings provided herein. The compounds are useful as CCR4 antagonists and are useful in treated diseases and conditions modulated by CCR4 activity.
Inventors:
FAN PINGCHEN (US)
LUI REBECCA M (US)
SCAMP RYAN J (US)
YANG JU (US)
WANG YU (US)
ZENG YIBIN (US)
ZHANG PENGLIE (US)
LUI REBECCA M (US)
SCAMP RYAN J (US)
YANG JU (US)
WANG YU (US)
ZENG YIBIN (US)
ZHANG PENGLIE (US)
Application Number:
PCT/US2023/065867
Publication Date:
February 22, 2024
Filing Date:
April 18, 2023
Export Citation:
Assignee:
CHEMOCENTRYX INC (US)
International Classes:
C07D403/04; C07D239/28; A61K31/505; A61P29/00; A61P35/00; A61P37/00
Attorney, Agent or Firm:
KEZER, William B. et al. (US)
Download PDF:
Previous Patent: ANTIBODIES AND METHODS TARGETING INTERLEUKIN-19
Next Patent: PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS
Next Patent: PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS